NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2025
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIOXA HD/EPIOXA KIT is a riboflavin 5-phosphate ophthalmic solution approved by the FDA in October 2025 for use via topical eye drops. The mechanism of action and specific indications are not publicly disclosed in available data, but the formulation targets ocular conditions treatable with riboflavin-based therapy. This represents Glaukos' entry into the ophthalmology market with a novel ophthalmic delivery system.
LOE Approaching2.1 years to LOE
With LOE approaching in 2028 and moderate competitive pressure (25% intensity), the brand team faces a compressed commercial window and will likely prioritize rapid market penetration and differentiation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on EPIOXA HD/EPIOXA KIT at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.